阅读说明：本技术 用于治疗年龄相关性黄斑变性的光生物调节治疗仪及使用方法 (Photobiological regulation therapeutic apparatus for treating age-related macular degeneration and using method ) 是由 寸青 杨文艳 陈琴 钟华 陶奕瑾 朱勤 钱朝旭 于 2021-01-12 设计创作，主要内容包括：本发明公开一种用于治疗年龄相关性黄斑变性的光生物调节治疗仪及使用方法,通过设定左右眼视镜相对发光视点亮度为600-800nm波长的近红外光,患者双眼在发光视点下进行治疗,每天4次,每次40秒,提高线粒体细胞色素c氧化酶活性,增加能量供应和细胞代谢,增强组织代谢修复,减缓年龄相关性黄斑变性患者视锥细胞死亡,为患者的视力恢复提供更大的可能性,本发明提出的技术方案安全性较高,低剂量红光治疗仪价格较低,患者治疗成本小,有利于普及。(The invention discloses a photobiological regulation therapeutic apparatus for treating age-related macular degeneration and a use method thereof.A patient treats both eyes of the patient under a luminous viewpoint by setting the brightness of the relative luminous viewpoint of a left eye sight and a right eye sight to be near infrared light with the wavelength of 800nm of 600-.)

1. The photobiological regulation therapeutic apparatus for treating age-related macular degeneration is characterized in that the relative luminous viewpoint brightness of a left eye visual mirror and a right eye visual mirror is set to be near infrared light with the wavelength of 600-.

2. The photobioregulatory therapy instrument for the treatment of age-related macular degeneration of claim 1, wherein the luminescence viewpoint is 630nm ± 10nm near infrared light.

3. The application method of the photobiological regulation therapeutic apparatus for treating age-related macular degeneration is characterized in that the eyes of a patient are treated under the luminous viewpoint 4 times a day and 40 seconds each time.

Technical Field

The invention relates to a therapeutic apparatus for age-related macular degeneration, in particular to a photobiological regulation therapeutic apparatus for treating age-related macular degeneration and a using method thereof.

Background

Age-related macular degeneration (AMD) is an eye disease with a positive incidence of age-related events, and it is widely accepted in the medical community that degeneration of the photoreceptors and underlying retinal pigment cells (RPE cells) in the macular region of the retina is one of the causative factors of AMD. As one of irreversible blinding eye diseases, statistics show that 8.7% of the global population suffers from AMD, and as the global population ages, the health care costs for AMD treatment in various countries will also rise year by year. AMD is clinically classified into a collapsed form (dry form) and an exudative form (wet form) according to different phenotypes, with dry AMD patients being the main and dry AMD being convertible to wet AMD. Dry AMD is characterized primarily by atrophic shedding of RPE cells, observed drusen, slow decline in central vision in patients, and severe patterns of advanced RPE atrophy, also known as Geographic Atrophy (GA). The clinical manifestations of wet AMD, which also include atrophic shedding of RPE cells and drusen formation, are distinguished from dry AMD by invasion of choroidal capillaries under the RPE and under the neural retina, forming Choroidal Neovascularization (CNV), resulting in exudation and hemorrhage, and rapid loss of vision and even blindness in the patient.

Aiming at the blindness caused by AMD, a great deal of drug research and development and clinical research are carried out in the medical field to explore a treatment scheme for delaying the progress of AMD and further curing AMD. Currently, for dry AMD, the focus of drug therapy is on relieving oxidative stress and inflammatory responses. Clinical trials of AMD patients taking antioxidant drugs were conducted in 2001 by the American national institutes of health eye institute, and follow-up results over five years have shown to help delay the progression of AMD but have no significant effect on the progression of GA. And then the formula of the antioxidant medicine is changed in 2006, and five-year clinical tests are carried out, so that the risk of developing dry AMD into wet AMD can be effectively reduced. Treatment of AMD, a major feature of wet AMD, is relatively diverse due to the high incidence of blindness shortly after the onset of wet AMD. Including local retinal laser photocoagulation therapy, transpupillary thermotherapy, photodynamic therapy, hormone therapy, anti-neogenesis drug-vascular drug therapy, surgical therapy and gene therapy. The earliest of these for AMD treatment laser photocoagulation presents an inapplicable CNV phenotype, and simple laser treatment has a high recurrence rate. Transpupillary thermotherapy has the advantage of less damage to the neuroretina and the disadvantage of having the potential to cause complications. Photodynamic therapy can effectively stabilize the vision of patients in a short period, but is easy to relapse and high in cost. The hormone therapy has weak therapeutic effect and high risk of complications, and can be used as preventive and combined therapy for participating in treatment. Surgical treatment is mostly used for massive macular hemorrhage with vitreoretinal massive fiber proliferation, or other therapies are ineffective, and problems to be solved such as high operation requirements and high risks exist. Gene therapy is currently in the development phase. The anti-neovascular drug therapy is the most attention-paid CNV treatment means at present, the injection of anti-Vascular Endothelial Growth Factor (VEGF) into the vitreous chamber can achieve the effects of preventing neovascular leakage, relieving macular edema and the like, and the anti-neovascular drug therapy has the advantages of small side effect, small visual impairment, simplicity in operation and the like, but has the defects of cost and risk improvement due to the need of repeated injection.

Disclosure of Invention

The present invention aims to overcome the defects in the prior art and provide a photobiological regulation therapeutic apparatus for treating age-related macular degeneration and a use method thereof.

The invention is realized by the following technical scheme: the photobiological regulation therapeutic apparatus for treating age-related macular degeneration is characterized in that the relative luminous viewpoint brightness of left and right eye sight glasses is set to be near infrared light with the wavelength of 600-.

Further, the luminous viewpoint is near infrared light of 630nm ± 10 nm.

The application method of the optical biological regulation therapeutic apparatus for treating age-related macular degeneration comprises the following steps: the patient was treated with both eyes at the light-emitting viewpoint 4 times a day for 40 seconds each time.

The invention has the advantages that:

in the retina of aged people with age-related macular degeneration, the number of cone cells, especially cone cells located in the fovea of the macula, is continuously reduced, so that cytochrome oxidase C is reduced, and the function of mitochondria is reduced. According to the technical scheme, the damage of the retinal nerve epithelial layer can be reduced through the protective effect of near infrared light on the retina, the photoreceptor is protected, the death of photoreceptor cells due to phototoxicity is avoided, and the polygene expression caused by photodamage is reduced; can inhibit degeneration of retinal ganglion cells; in addition, the activity of mitochondrial cytochrome c oxidase is improved by near infrared light, energy supply and cell metabolism are increased, tissue metabolism repair is enhanced, cone cell death of age-related macular degeneration patients is slowed down, disease progression is slowed down, and useful eyesight is prolonged.

The device of the invention has higher treatment safety, and the low-dose red light is used for treating myopia for decades. In addition, the low-dose red light therapeutic apparatus has lower price and low treatment cost for patients, and is beneficial to popularization.

Drawings

FIG. 1 is a schematic view of the biological regulating apparatus of the present invention.

In the figure: 1-luminous viewpoint, 2-left and right sight glasses.

Detailed Description

The present invention is further illustrated by the following examples, which are intended to be purely exemplary and are not intended to limit the scope of the invention, as various equivalent modifications of the invention will occur to those skilled in the art upon reading the present disclosure and fall within the scope of the appended claims.

The near-infrared light is the near-infrared light with the spectral range of 600-1100nm generated by the light-emitting diode. The light receptor in the cell is sensitive to the wave band, particularly 600-700nm is an optical window for in-vivo treatment, the penetrating power is strong but not enough to cause tissue cell damage, the light receptor in the cell is activated, a signal channel is triggered, the cell metabolism is influenced, and the light energy is converted into the metabolic energy. Near infrared light has been shown to significantly increase the activity of cytochrome oxidase and superoxide dismutase, suggesting beneficial effects in inducing metabolism and antioxidant effects. In addition, near infrared light may also promote cerebral blood flow and cognitive function in humans without adverse effects.

The near infrared light has a protective effect on retina, can reduce damage of retinal nerve epithelial layer, protect photoreceptors, avoid death of photoreceptor cells due to phototoxicity, and reduce polygene expression caused by photodamage; can inhibit degeneration of retinal ganglion cells; in addition, it also has antioxidant effect.

Therefore, the invention designs a photobiological regulation therapeutic apparatus for treating age-related macular degeneration, as shown in figure 1, the apparatus adopts near infrared light with the brightness of 600 plus 800nm relative to a luminous viewpoint 1 of a left eye glass 2 and a right eye glass 2, and the principle and the method are that the retina of an age-related macular degeneration patient is irradiated by low-dose red light for 4 times every day and 40 seconds every time so as to slow down the occurrence and the development of the age-related macular degeneration. Treatment was continued until the visual field was stable. In addition to the photo-biological regulation therapeutic apparatus provided by the invention, various photo-biological regulation therapeutic apparatuses on the market can be selected, for example, the amblyopia comprehensive therapeutic apparatus produced by Zuozhou industrial park Zuoguan medical apparatus Limited company, and the apparatus which can only regulate the red light to the wavelength of 600-800nm belongs to the design spirit of the invention.

The above-described embodiments are merely illustrative of the preferred embodiments of the present invention, and do not limit the scope of the present invention, and various modifications and improvements of the technical solutions of the present invention can be made by those skilled in the art without departing from the spirit of the present invention, and the technical solutions of the present invention are within the scope of the present invention defined by the claims.